Sally Martin

Dr Sally Martin

Senior Lecturer

School of Pharmacy and Biomedical Sciences

College of Health

Dr Martin is a teaching-focussed academic in the School of Biomedicine, University of Adelaide. She is currently the course coordinator of Human Anatomy and Physiology 1A (ANAT SC 1102) and Human Anatomy and Physiology 1B (ANAT SC 1103), and also teaches into Create.Communicate.Connect (HLTH SC 1002) and Foundations of Medicine (MEDIC ST 1501). Dr Martin is an Education Specialist and is a member of the Adelaide Education Academy, and sits on the BHMS Learning & Teaching Committee (Academic Lead, First Year Student Experience), the BHMS Academic Review Committee (ARC), and the School of Biomedicine Course Monitoring and Evaluation committee.Dr Martin completed her PhD on bone marrow angiogenesis and osteolytic bone disease in the haematological malignancy, multiple myeloma in 2009. Following the completion of her PhD, Dr Martin worked as a post-doctoral research at the Institute of Medical and Veterinary Science, SA Pathology, and SAHMRI, examining the role of the PI3K and mTOR signalling pathways in bone development, and how these pathways could be exploited to stimulate bone formation in disease settings such as osteoporosis and tumour-associated bone loss. Her more recent projects included investigating (1) the role of the mTOR signalling pathways in mesenchymal stem cell biology, (2) the role of the mTOR signalling pathways in regulating skeletal biology and bone remodelling, and (3) the role of skeletal mTORC1 signalling in B-cell development and glucose homeostasis.

Date Position Institution name
2019 - ongoing Lecturer, Course Coordinator University of Adelaide
2015 - 2019 Post-doctoral Researcher University of Adelaide, Adelaide
2012 - 2019 Affiliate Lecturer University of Adelaide
2009 - 2015 Post-doctoral Researcher SA Pathology
2003 - 2008 Technical Assistant (part-time) Institute of Medical and Veterinary Science (IMVS)

Date Institution name Country Title
2005 - 2008 University of Adelaide, Adelaide Australia PhD
2000 - 2004 University of South Australia Australia Bachelor of Medical and Pharmaceutical Biotechnology (Hons)

Year Citation
2021 Tangseefa, P., Martin, S. K., Chin, P. Y., Breen, J., Mah, C. Y., Baldock, P. A., . . . Zannettino, A. C. W. (2021). The mTORC1 complex in pre-osteoblasts regulates whole-body energy metabolism independently of osteocalcin. Bone Research, 9(1), 10-1-10-17.
DOI Scopus10 WoS12 Europe PMC12
2021 Tangseefa, P., Martin, S. K., Arthur, A., Panagopoulos, V., Page, A. J., Wittert, G. A., . . . Zannettino, A. C. W. (2021). Deletion of Rptor in preosteoblasts reveals a role for the mammalian target of rapamycin complex 1 (mTORC1) complex in dietary-induced changes to bone mass and glucose homeostasis in female mice. JBMR Plus, 5(5), 1-14.
DOI Scopus4 WoS4 Europe PMC4
2020 Xie, J., Shen, K., Jones, A. T., Yang, J., Tee, A. R., Shen, M. H., . . . Proud, C. G. (2020). Reciprocal signaling between mTORC1 and MNK2 controls cell growth and oncogenesis.. Cellular and molecular life sciences : CMLS, 78(1), 249-270.
DOI Scopus18 WoS21 Europe PMC17
2018 Martin, S., Fitter, S., El Khawanky, N., Grose, R., Walkley, C., Purton, L., . . . Zannettino, A. (2018). mTORC1 plays an important role in osteoblastic regulation of B-lymphopoiesis. Scientific Reports, 8(1), 14501-1-14501-10.
DOI Scopus17 WoS16 Europe PMC16
2018 Tangseefa, P., Martin, S., Fitter, S., Baldock, P., Proud, C., & Zannettino, A. (2018). Osteocalcin-dependent regulation of glucose metabolism and fertility: skeletal implications for the development of insulin resistance. Journal of Cellular Physiology, 233(5), 3769-3783.
DOI Scopus20 WoS17 Europe PMC15
2017 Vandyke, K., Zeissig, M., Hewett, D., Martin, S., Mrozik, K., Cheong, C., . . . Zannettino, A. (2017). HIF-2α promotes dissemination of plasma cells in multiple myeloma by regulating CXCL12/CXCR4 and CCR1. Cancer Research, 77(20), 5452-5463.
DOI Scopus50 WoS47 Europe PMC44
2017 Fitter, S., Matthews, M., Martin, S., Xie, J., Ooi, S., Walkley, C., . . . Zannettino, A. (2017). mTORC1 plays an important role in skeletal development by controlling preosteoblast differentiation. Molecular and Cellular Biology, 37(7), e00668-1-e00668-20.
DOI Scopus57 WoS53 Europe PMC52
2015 Gan, Z., Fitter, S., Vandyke, K., To, L., Zannettino, A., & Martin, S. (2015). The effect of the dual PI3K and mTOR inhibitor BEZ235 on tumour growth and osteolytic bone disease in multiple myeloma. European Journal of Haematology, 94(4), 343-354.
DOI Scopus35 WoS33 Europe PMC29
2015 Martin, S., Fitter, S., Dutta, A., Matthews, M., Walkley, C., Hall, M., . . . Zannettino, A. (2015). Brief report: The differential roles of mTORC1 and mTORC2 in mesenchymal stem cell differentiation. Stem Cells, 33(4), 1359-1365.
DOI Scopus81 WoS77 Europe PMC73
2015 Martin, S., Gan, Z., Fitter, S., To, L., & Zannettino, A. (2015). The effect of the PI3K inhibitor BKM120 on tumour growth and osteolytic bone disease in multiple myeloma. Leukemia Research, 39(3), 380-387.
DOI Scopus21 WoS19 Europe PMC16
2015 Cheong, C., Chow, A., Fitter, S., Hewett, D., Martin, S., Williams, S., . . . Vandyke, K. (2015). Tetraspanin 7 (TSPAN7) expression is upregulated in multiple myeloma patients and inhibits myeloma tumour development in vivo. Experimental Cell Research, 332(1), 24-38.
DOI Scopus36 WoS36 Europe PMC35
2015 Forristal, C. E., Brown, A. L., Helwani, F. M., Winkler, I. G., Nowlan, B., Barbier, V., . . . Levesque, J. P. (2015). Hypoxia inducible factor (HIF)-2α accelerates disease progression in mouse models of leukemia and lymphoma but is not a poor prognosis factor in human AML. Leukemia, 29(10), 2075-2085.
DOI Scopus34 WoS34 Europe PMC37
2011 Martin, S., Diamond, P., Gronthos, S., Peet, D., & Zannettino, A. (2011). The emerging role of hypoxia, HIF-1 and HIF-2 in multiple myeloma. Leukemia, 25(10), 1533-1542.
DOI Scopus111 WoS102 Europe PMC95
2010 Martin, S., Fitter, S., Bong, L., Drew, J., Gronthos, S., Shepherd, P., & Zannettino, A. (2010). NVP-BEZ235, a dual pan class I PI3 kinase and mTOR inhibitor, promotes osteogenic differentiation in human mesenchymal stromal cells. Journal of Bone and Mineral Research, 25(10), 2126-2137.
DOI Scopus53 WoS51 Europe PMC48
2010 Williams, S., Martin, S., Vincent, C., Gronthos, S., Zheng, T., Atkins, G., & Zannettino, A. (2010). Circulating levels of TWEAK correlate with bone erosion in multiple myeloma patients. British Journal of Haematology, 150(3), 373-376.
DOI Scopus6 WoS6 Europe PMC4
2010 Martin, S., Diamond, P., Williams, S., To, L., Peet, D., Fujii, N., . . . Zannettino, A. (2010). Hypoxia-inducible factor-2 is a novel regulator of aberrant CXCL12 expression in multiple myeloma plasma cells. Haematologica, 95(5), 776-784.
DOI Scopus86 WoS79 Europe PMC67
2010 Psaltis, P., Paton, S., See, F., Arthur, A., Martin, S., Itescu, S., . . . Zannettino, A. (2010). Enrichment for STRO-1 expression enhances the cardiovascular paracrine activity of human bone marrow-derived mesenchymal cell populations. Journal of Cellular Physiology, 223(2), 530-540.
DOI Scopus134 WoS124 Europe PMC111
2009 Diamond, P., Labrinidis, A., Martin, S., Farrugia, A., Gronthos, S., To, L., . . . Zannettino, A. (2009). Targeted disruption of the CXCL12/CXCR4 axis inhibits osteolysis in a murine model of myeloma-associated bone loss. Journal of Bone and Mineral Research, 24(7), 1150-1161.
DOI Scopus62 WoS63 Europe PMC52
2009 Labrinidis, A., Diamond, P., Martin, S., Hay, S., Liapis, V., Zinonos, I., . . . Evdokiou, A. (2009). Apo2L/TRAIL inhibits tumor growth and bone destruction in a murine model of multiple myeloma. Clinical Cancer Research, 15(6), 1998-2009.
DOI Scopus33 WoS31 Europe PMC30
2006 Martin, S., Dewar, A., Farrugia, A., Horvath, N., Gronthos, S., To, L., & Zannettino, A. (2006). Tumor angiogenesis is associated with plasma levels of stromal-derived factor-1α in patients with multiple myeloma. Clinical Cancer Research, 12(23), 6973-6977.
DOI Scopus33 WoS30 Europe PMC25
2005 Zannettino, A., Farrugia, A., Kortesidis, A., Manavis, J., To, L., Martin, S., . . . Gronthos, S. (2005). Elevated serum levels of stromal-derived factor-1α are associated with increased osteoclast activity and osteolytic bone disease in multiple myeloma patients. Cancer Research, 65(5), 1700-1709.
DOI Scopus187 WoS173 Europe PMC144
2004 Martin, S., To, L., Horvath, N., & Zannettino, A. (2004). Angiogenesis in multiple myeloma: Implications in myeloma therapy. Cancer Reviews: Asia-Pacific, 2(2), 119-129.
DOI

Year Citation
2008 Zannettino, A., Martin, S. K., Gronthos, S., To, L., & Peet, D. (2008). The role of CXCL12 in multiple myeloma. In F. columbus (Ed.), Cancer Research Progress. Nova Science Publishers.

Year Citation
2018 Tangseefa, P., Martin, S. K., Wilczek, V., Baldock, P., Proud, C. G., Fitter, S., & Zannettino, A. C. W. (2018). Metabolic and reproductive abnormalities in mice with impaired skeletal-mTORC1 function mirror a dietary restriction phenotype. In CLINICAL ENDOCRINOLOGY Vol. 89 (pp. 19). Perth, AUSTRALIA: WILEY.
2017 Zeissig, M. N., Hewett, D. R., Martin, S., Mrozik, K. M., Cheong, C. M., Diamond, P., . . . Zannettino, A. C. W. (2017). HIF-2α Upregulates CCR1 to Promote Dissemination of Plasma Cells in Multiple Myeloma. In BLOOD Vol. 130 (pp. 2 pages). Atlanta, GA: AMER SOC HEMATOLOGY.
2013 Forristal, C. E., Helwani, F., Martin, S., Nowlan, B., Winkler, I. G., Zannettino, A., & Levesque, J. -P. (2013). Hypoxia Inducible Factor (HIF)-2α Enhances Proliferation Of Malignant Hematopoietic Cells In The Hypoxic Malignant Bone Marrow. In BLOOD Vol. 122 (pp. 2 pages). New Orleans, LA: AMER SOC HEMATOLOGY.
DOI WoS1
2008 Martin, S. K., Diamond, P., To, L. B., Pect, D., Gronthos, S., & Zannettino, A. W. W. (2008). CXCL12 Expression Is Regulated by HIF-2a in Multiple Myeloma Plasma Cells. In JOURNAL OF BONE AND MINERAL RESEARCH Vol. 23 (pp. S262). Montreal, CANADA: AMER SOC BONE & MINERAL RES.
2008 Diamond, P., Labrinidis, A., Martin, S. K., Farrugia, A., Gronthos, S., To, L. B., . . . Zannettino, A. (2008). CXCL12 stimulates osteoclastic bone resorption in a novel mouse model of human multiple myeloma. In Journal of Bone and Mineral Research Vol. 23 (pp. S262). Montreal: American Society for Bone and Mineral Research.
2007 Martin, S. K., Dewar, A., Farrugia, A., Horvath, N., Gronthos, S., To, L. B., & Zannettino, A. (2007). Tumour angiogenesis is associated with plasma levels of stromal-derived factor-1a in patients with multiple myeloma. In Haematologica Vol. 92 (pp. 125-126). Kos, Greece: Ferrata Storti Foundation.
2007 Martin, S. K., Dewar, A. L., Farrugia, A. N., Horvath, N., Gronthos, S., To, L. B., & Zannettino, A. C. W. (2007). Tumour angiogenesis correlates with plasma levels of CXCL12 in patients with multiple myeloma. In HAEMATOLOGICA-THE HEMATOLOGY JOURNAL Vol. 92 (pp. 125-126). Kos Isl, GREECE: FERRATA STORTI FOUNDATION.
2007 Diamond, P., Labrinidis, A., Martin, S. K., Farrugia, A. N., Gronthos, S., To, L. B., . . . Zannettino, A. C. W. (2007). CXCL12 stimulates osteoclastic bone resorption in a novel mouse model of human multiple myeloma. In HAEMATOLOGICA-THE HEMATOLOGY JOURNAL Vol. 92 (pp. 130). Kos Isl, GREECE: FERRATA STORTI FOUNDATION.

Year Citation
2013 Forristal, C., Helwani, F., Nowlan, B., Martin, S., Zannetino, A., & Levesque, J. -P. (2013). HYPOXIA INDUCIBLE FACTOR (HIF)-2 alpha ENHANCES PROLIFERATION OF MALIGNANT HAEMATOPOIETIC CELLS IN THE HYPOXIC MALIGNANT BONE MARROW. Poster session presented at the meeting of EXPERIMENTAL HEMATOLOGY. Vienna, AUSTRIA: ELSEVIER SCIENCE INC.
DOI

Diabetes Australia grant (2020), Investigating the mechanisms by which bone-specific mTORC1 inhibition protects mice against diet-induced insulin resistance” AUD $60,000.

University of Adelaide ECR Mentored Project Development Grant (2018), The role of bone-derived secretagogues in men with Type 2 diabetes” AUD $13,179.      

Mary Overton Early Career Research Fellowship (2012 - 2015), The role of the raptor and rictor signalling pathways in skeletal biology, AUD$252,000

Centre for Stem Cell Research Project Grant 2012, The role of raptor and rictor in MSC differentiation, AUD$75,000

Novartis Pharmaceuticals Project Grant 2011, Can the dual PI3K/mTOR inhibitor NVP-BEZ235 be used to stimulate bone formation in multiple myeloma? AUD$75,000.

Human Anatomy and Physiology A (HBIO_1002)

Human Anatomy and Physiology B (HBIO_1003)

Foundations of Medicine (MEDIC ST 1501)

Date Role Research Topic Program Degree Type Student Load Student Name
2017 - 2020 Co-Supervisor The Role of Osteoblast-mTORC1 in the Regulation of Glucose Metabolism Doctor of Philosophy Doctorate Full Time Miss Pawanrat Tangseefa
2013 - 2018 Co-Supervisor The Role of mTORC1 in Mesenchymal Stem Cell Fate Determination, Osteoblast Differentiation and Skeletal Development Doctor of Philosophy Doctorate Part Time Ms Mary Patricia Matthews

Date Role Board name Institution name Country
2021 - ongoing Board Member BHMS Program Learning & Teaching Committee University of Adelaide Australia
2019 - 2020 Member Allied Health Programs Board University of Adelaide Australia

Date Role Committee Institution Country
2021 - ongoing Member BHMS Academic Review Committee University of Adelaide Australia
2021 - ongoing Member School of Biomedicine Course Monitoring and Evaluation Committee University of Adelaide Australia

Date Role Membership Country
2024 - ongoing Member HERDSA Australia
2023 - ongoing Member Adelaide Education Academy Australia
2022 - ongoing Member Women’s Professional Development Network Australia

Connect With Me

External Profiles

Other Links